Literature DB >> 6210475

The effect of cyclosporin A on peripheral blood T cell subpopulations in renal allografts.

P Sweny, N Tidman.   

Abstract

Treatment with cyclosporin A (CyA) produces a reversal of the normal ratio of OKT4+ (inducer type) to OKT84 (suppressor-cytotoxic type) cells so that renal allograft recipients on CyA alone develop a four-fold increase in the absolute number of circulating OKT8 positive cells. Conventional immunosuppression with azathioprine and prednisolone reduces both populations of T cells without altering the ratio of OKT4+ to OKT8+ cells. This effect of CyA may help to explain its action as an immunosuppressive agent.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6210475      PMCID: PMC1536520     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Long-term T-cell-mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving cyclosporin A.

Authors:  D H Crawford; P Sweny; J M Edwards; G Janossy; A V Hoffbrand
Journal:  Lancet       Date:  1981-01-03       Impact factor: 79.321

2.  Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft.

Authors:  D H Crawford; J A Thomas; G Janossy; P Sweny; O N Fernando; J F Moorhead; J H Thompson
Journal:  Lancet       Date:  1980-06-21       Impact factor: 79.321

3.  Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity.

Authors:  J F Borel
Journal:  Immunology       Date:  1976-10       Impact factor: 7.397

4.  Cyclosporin A blocks receptors for HLA-DR antigens on T cells.

Authors:  R Palacios; G Möller
Journal:  Nature       Date:  1981-04-30       Impact factor: 49.962

5.  Effect of cyclosporin A on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR.

Authors:  A D Hess; P J Tutschka
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

6.  Effect of cyclosporin A on human lymphocyte responses in vitro. II. Induction of specific alloantigen unresponsiveness mediated by a nylon wool adherent suppressor cell.

Authors:  A D Hess; P J Tutschka; G W Santos
Journal:  J Immunol       Date:  1981-03       Impact factor: 5.422

7.  Nephrotoxicity of cyclosporin A in liver and kidney transplant patients.

Authors:  G B Klintmalm; S Iwatsuki; T E Starzl
Journal:  Lancet       Date:  1981-02-28       Impact factor: 79.321

8.  Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines.

Authors:  A G Bird; S M McLachlan; S Britton
Journal:  Nature       Date:  1981-01-22       Impact factor: 49.962

9.  Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation.

Authors:  R L Powles; H M Clink; D Spence; G Morgenstern; J G Watson; P J Selby; M Woods; A Barrett; B Jameson; J Sloane; S D Lawler; H E Kay; D Lawson; T J McElwain; P Alexander
Journal:  Lancet       Date:  1980-02-16       Impact factor: 79.321

10.  Sixteen months experience with cyclosporin-A in human kidney transplantation.

Authors:  P Sweny; K Farrington; F Younis; Z Varghese; R A Baillod; O N Fernando; J F Moorhead
Journal:  Transplant Proc       Date:  1981-03       Impact factor: 1.066

View more
  8 in total

1.  Human immune responses in vivo to protein (KLH) and polysaccharide (DNP-Ficoll) neoantigens: normal subjects compared with bone marrow transplant patients on cyclosporine.

Authors:  P L Amlot; A E Hayes; D Gray; E C Gordon-Smith; J H Humphrey
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

2.  Peripheral blood T lymphocytes found in renal allograft recipients treated with cyclosporine.

Authors:  M Liebert; J T Rosenthal; E Merrall; R J Taylor; G Singh; T E Starzl; B S Rabin; T R Hakala
Journal:  Transplantation       Date:  1983-08       Impact factor: 4.939

3.  Prognostic value of T lymphocyte subset ratios for renal transplant survival in patients on different immunosuppressive regimens.

Authors:  F C Henny; A van Es; P J Oljans; W M Baldwin; H J Tanke; L A van Es; L C Paul
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

4.  Effects of cyclosporine in experimental cryptococcal meningitis.

Authors:  J R Perfect; D T Durack
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

5.  Natural killer-cell activity, interferon-alpha 2 production, and interleukin-2 production in cyclosporine-treated and conventionally immunosuppressed human allograft recipients.

Authors:  P J Guillou; G R Giles; C W Ramsden
Journal:  J Clin Immunol       Date:  1986-09       Impact factor: 8.317

6.  Depletion of lymphocytes with membrane markers of helper phenotype: a feature of acute and chronic drug-induced immunosuppression.

Authors:  E Dupont; L Schandene; R Devos; M Lambermont; J Wybran
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

7.  [The effect of rejection crises and immunosuppressive therapy on the lymphocyte subpopulations of patients after kidney transplantation].

Authors:  A v Kiparski; D Frei; W Fierz; G Frei; G Uhlschmid; F Largiader; U Binswanger
Journal:  Klin Wochenschr       Date:  1990-04-17

Review 8.  Cyclosporine: immunology, toxicity and pharmacology in experimental animals.

Authors:  A W Thomson; P H Whiting; J G Simpson
Journal:  Agents Actions       Date:  1984-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.